Internal Medicine, Rheumatology · Thomasville, GA
NPI
1083811442
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
10
Medicare group memberships
Hospitals
4
Hospital affiliations
235 W Jackson St
Thomasville, GA, 31792
Phone (229) 236-5455
Groups this clinician bills Medicare through
Medicare paid, 2024
$86K
2,739 services
Medicare patients, 2024
393
Average age 72
Drug cost, 2024
$9.7M
4,042 prescriptions
Company payments, 2025
$28K
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James M Hunt was code 36415 (venipuncture blood collection), 375 times for 228 patients. In total James M Hunt billed 2,739 services in 26 codes, and Medicare paid $86K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 375 | 228 | $8.47 | $3,175 |
| 99214 Office E&M - Established | Office | 331 | 205 | $79.05 | $26K |
| 99204 Office E&M - New | Office | 88 | 88 | $101.96 | $8,972 |
| 99205 Office E&M - New | Office | 80 | 80 | $147.37 | $12K |
| 99213 Office E&M - Established | Office | 62 | 57 | $56.69 | $3,515 |
| 99215 Office E&M - Established | Office | 53 | 42 | $111.32 | $5,900 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 49 | 24 | $0.66 | $32.54 |
| 99222 Hospital E&M - Initial | Facility | 46 | 46 | $93.23 | $4,289 |
| 99223 Hospital E&M - Initial | Facility | 36 | 35 | $126.60 | $4,558 |
| 20610 Joint Injection | Office | 18 | 15 | $44.01 | $792 |
| 99442 Telephone Services | Office | 17 | 13 | $52.77 | $897 |
By year: 2022 $65K for 1,998 services; 2023 $51K for 1,104 services; 2024 $86K for 2,739 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 375 | 228 | $8.47 | $3,175 |
Medicare prescription drug claims, 2024
In 2024, the drug James M Hunt prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 409 prescriptions and refills. In total James M Hunt wrote 4,042 Medicare prescriptions that cost $9.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 409 | 1,092 | 151 | $20K |
| Methotrexate Methotrexate Sodium | 401 | 957 | 162 | $8,224 |
| Gabapentin Generic | 303 | 748 | 123 | $3,951 |
| Allopurinol Generic | 287 | 771 | 99 | $3,275 |
| Prednisone Generic | 278 | 505 | 129 | $2,738 |
| Rinvoq Upadacitinib | 268 | 278 | 36 | $1.8M |
| Enbrel Sureclick Etanercept | 173 | 173 | 23 | $1.3M |
| Tramadol Hcl Generic | 144 | 144 | 47 | $1,061 |
| Humira(Cf) Pen Adalimumab | 139 | 139 | 17 | $1.0M |
| Leflunomide Generic | 122 | 295 | 41 | $7,427 |
| Mycophenolate Mofetil Generic | 110 | 259 | 41 | $14K |
| Colchicine Generic | 88 | 218 | 36 | $7,435 |
| Meloxicam Generic | 82 | 228 | 43 | $452 |
| Orencia Clickject Abatacept | 78 | 78 | 11 | $442K |
| Krystexxa Pegloticase | 71 | 71 | Under 11 | $2.5M |
Brand drugs: - claims; generic drugs: 2,869 claims; opioid claims: 200.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James M Hunt $28K ($28K in general payments such as food, travel and fees) from 18 companies. The largest payer was Amgen Inc. with $27K.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 56 | $27K |
| Janssen Biotech, Inc. JNJ | 16 | $337 |
| GlaxoSmithKline, LLC. GSK | 10 | $182 |
| Abbvie Inc. ABBV | 12 | $171 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $165 |
| Organon LLC OGN | 5 | $69.44 |
| Mallinckrodt Hospital Products Inc. | 3 | $68.95 |
| UCB, Inc. UCB.BR | 4 | $67.11 |
| Pfizer Inc. PFE | 4 | $63.87 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $46.33 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.